{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:45:12Z","timestamp":1787003112687,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["92169202"],"award-info":[{"award-number":["92169202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82130101"],"award-info":[{"award-number":["82130101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2307800"],"award-info":[{"award-number":["2023YFC2307800"]}]},{"name":"Youth Innovation Promotion Association CAS program","award":["2021333"],"award-info":[{"award-number":["2021333"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Coronaviruses remain a challenge due to the limited or incomplete protection provided by existing vaccines, highlighting the need for improved antigen-based designs that can reduce mortality, block transmission, and provide long-lasting, broad-spectrum protection. In this study, we adapted artificial antibody strategies to display receptor-binding domains (RBDs) from representative human coronaviruses, utilizing an engineered human IgG1 framework modified at the Fab and Fc domains to support diverse antigen presentation and enhanced immunopotentiation. The results indicate that bivalent, tetravalent, and multivalent RBD constructs developed within this framework confer broad-spectrum immune protection against severe acute respiratory syndrome coronavirus 2 and other pathogenic coronaviruses. Moreover, Fc-mediated antigen delivery, primarily engaging the neonatal Fc\u03b3 receptor, enhances mucosal, cellular, and sustained immune responses. This underscores the versatility and practical utility of the modified IgG1 framework, based on artificial antibody strategies, for developing broad-spectrum mucosal vaccine antigens, representing promising vaccine candidates targeting human coronaviruses.<\/jats:p>","DOI":"10.1038\/s41541-026-01375-2","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:06:46Z","timestamp":1769602006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Universal broad-spectrum mucosal vaccine design for human coronaviruses inspired by artificial antibodies"],"prefix":"10.1038","volume":"11","author":[{"given":"Yan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenshu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"1375_CR1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","volume":"24","author":"S Su","year":"2016","unstructured":"Su, S. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 24, 490\u2013502 (2016).","journal-title":"Trends Microbiol."},{"key":"1375_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"1375_CR3","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S1473-3099(24)00738-2","volume":"25","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations. Lancet Infect. Dis. 25, e6\u2013e7 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1375_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/d41586-021-03619-8","volume":"600","author":"E Callaway","year":"2021","unstructured":"Callaway, E. Beyond Omicron: what\u2019s next for COVID\u2019s viral evolution. Nature 600, 204\u2013207 (2021).","journal-title":"Nature"},{"key":"1375_CR5","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2025.01.042","volume":"188","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor. Cell 188, 1729\u20131742.e1716 (2025).","journal-title":"Cell"},{"key":"1375_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell 182, 1284\u20131294.e1289 (2020).","journal-title":"Cell"},{"key":"1375_CR7","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1016\/j.immuni.2022.08.017","volume":"55","author":"SA Wellford","year":"2022","unstructured":"Wellford, S. A. et al. Mucosal plasma cells are required to protect the upper airway and brain from infection. Immunity 55, 2118\u20132134.e2116 (2022).","journal-title":"Immunity"},{"key":"1375_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/vaccines12070714","volume":"12","author":"M Kumari","year":"2024","unstructured":"Kumari, M. et al. Multivalent mRNA vaccine elicits broad protection against SARS-CoV-2 variants of concern. Vaccines 12, 714 (2024).","journal-title":"Vaccines"},{"key":"1375_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/s41423-022-00929-3","volume":"19","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern. Cell Mol. Immunol. 19, 1279\u20131289 (2022).","journal-title":"Cell Mol. Immunol."},{"key":"1375_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303366","volume":"11","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Mosaic RBD nanoparticles elicit protective immunity against multiple human coronaviruses in animal models. Adv. Sci. 11, e2303366 (2024).","journal-title":"Adv. Sci."},{"key":"1375_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo3332","volume":"15","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Vaccination with S(pan), an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice. Sci. Transl. Med. 15, eabo3332 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1375_CR12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167306","volume":"8","author":"T Tada","year":"2023","unstructured":"Tada, T., Peng, J. Y., Dcosta, B. M. & Landau, N. R. Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model. JCI Insight 8, e167306 (2023).","journal-title":"JCI Insight"},{"key":"1375_CR13","doi-asserted-by":"publisher","DOI":"10.4110\/in.2024.24.e19","volume":"24","author":"SH Kim","year":"2024","unstructured":"Kim, S. H. et al. Influenza virus-derived CD8 T cell epitopes: implications for the development of universal influenza vaccines. Immune Netw. 24, e19 (2024).","journal-title":"Immune Netw."},{"key":"1375_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2192817","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu, Z., Lu, L. & Jiang, S. Application of \u201cB+1\u201d heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines. Emerg. Microbes Infect. 12, 2192817 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"1375_CR15","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","volume":"395","author":"V Tricou","year":"2020","unstructured":"Tricou, V. et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet 395, 1434\u20131443 (2020).","journal-title":"Lancet"},{"key":"1375_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00597-4","volume":"7","author":"F Zhao","year":"2022","unstructured":"Zhao, F., Zai, X., Zhang, Z., Xu, J. & Chen, W. Challenges and developments in universal vaccine design against SARS-CoV-2 variants. NPJ Vaccines 7, 167 (2022).","journal-title":"NPJ Vaccines"},{"key":"1375_CR17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.180784","volume":"9","author":"B Sun","year":"2024","unstructured":"Sun, B. et al. An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA. JCI Insight 9, e180784 (2024).","journal-title":"JCI Insight"},{"key":"1375_CR18","doi-asserted-by":"publisher","first-page":"pgae183","DOI":"10.1093\/pnasnexus\/pgae183","volume":"3","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters. PNAS Nexus 3, pgae183 (2024).","journal-title":"PNAS Nexus"},{"key":"1375_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adh1655","volume":"9","author":"G Baldeon Vaca","year":"2023","unstructured":"Baldeon Vaca, G. et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Sci. Adv. 9, eadh1655 (2023).","journal-title":"Sci. Adv."},{"key":"1375_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42796-0","volume":"14","author":"W Li","year":"2023","unstructured":"Li, W. et al. An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission. Nat. Commun. 14, 7114 (2023).","journal-title":"Nat. Commun."},{"key":"1375_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59353-6","volume":"16","author":"AK Anthi","year":"2025","unstructured":"Anthi, A. K. et al. An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models. Nat. Commun. 16, 3999 (2025).","journal-title":"Nat. Commun."},{"key":"1375_CR22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.4049\/jimmunol.2100297","volume":"207","author":"SP Ochsner","year":"2021","unstructured":"Ochsner, S. P. et al. FcRn-targeted mucosal vaccination against influenza virus infection. J. Immunol. 207, 1310\u20131321 (2021).","journal-title":"J. Immunol."},{"key":"1375_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJMp2118468","volume":"386","author":"DM Morens","year":"2022","unstructured":"Morens, D. M., Taubenberger, J. K. & Fauci, A. S. Universal coronavirus vaccines - an urgent need. N. Engl. J. Med. 386, 297\u2013299 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1375_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-025-01678-2","volume":"18","author":"Y Wu","year":"2025","unstructured":"Wu, Y. et al. Anti-TGF-beta\/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis. J. Hematol. Oncol. 18, 24 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"1375_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/bs.apcsb.2024.11.001","volume":"144","author":"S Tapryal","year":"2025","unstructured":"Tapryal, S. Monoclonal antibodies - a repertoire of therapeutics. Adv. Protein Chem. Struct. Biol. 144, 151\u2013212 (2025).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"1375_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41421-021-00320-y","volume":"7","author":"X Pan","year":"2021","unstructured":"Pan, X. et al. RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. Cell Discov. 7, 82 (2021).","journal-title":"Cell Discov."},{"key":"1375_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01279-23","volume":"97","author":"Y Wu","year":"2023","unstructured":"Wu, Y. et al. Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants. J. Virol. 97, e0127923 (2023).","journal-title":"J. Virol."},{"key":"1375_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104868","volume":"182","author":"X Pan","year":"2020","unstructured":"Pan, X. et al. Immunoglobulin fragment F(ab\u2019)(2) against RBD potently neutralizes SARS-CoV-2 in vitro. Antivir. Res. 182, 104868 (2020).","journal-title":"Antivir. Res."},{"key":"1375_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/cimm.2000.1617","volume":"200","author":"D Xu","year":"2000","unstructured":"Xu, D. et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 200, 16\u201326 (2000).","journal-title":"Cell Immunol."},{"key":"1375_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ymeth.2013.06.035","volume":"65","author":"O Vafa","year":"2014","unstructured":"Vafa, O. et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 65, 114\u2013126 (2014).","journal-title":"Methods"},{"key":"1375_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2015.12.033","volume":"223","author":"S Foss","year":"2016","unstructured":"Foss, S. et al. Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization. J. Control Release 223, 42\u201352 (2016).","journal-title":"J. Control Release"},{"key":"1375_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105634","volume":"114","author":"W Ruan","year":"2025","unstructured":"Ruan, W. et al. SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion. EBioMedicine 114, 105634 (2025).","journal-title":"EBioMedicine"},{"key":"1375_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-022-00612-2","volume":"32","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 32, 269\u2013287 (2022).","journal-title":"Cell Res."},{"key":"1375_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg1143","volume":"13","author":"Y Wu","year":"2021","unstructured":"Wu, Y. et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci. Transl. Med. 13, eabg1143 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1375_CR35","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-023-06809-8","volume":"624","author":"T Ye","year":"2023","unstructured":"Ye, T. et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature 624, 630\u2013638 (2023).","journal-title":"Nature"},{"key":"1375_CR36","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.cell.2022.04.029","volume":"185","author":"K Xu","year":"2022","unstructured":"Xu, K. et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 185, 2265\u20132278.e2214 (2022).","journal-title":"Cell"},{"key":"1375_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"1375_CR38","first-page":"126","volume":"3","author":"J Zhang","year":"2020","unstructured":"Zhang, J., Yi, J. & Zhou, P. Development of bispecific antibodies in China: overview and prospects. Antib. Ther. 3, 126\u2013145 (2020).","journal-title":"Antib. Ther."},{"key":"1375_CR39","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s41587-024-02486-8","volume":"42","author":"J Seo","year":"2024","unstructured":"Seo, J., Polster, J., Israelow, B., Corbett-Helaire, K. S. & Martinez, D. R. Challenges for developing broad-based mucosal vaccines for respiratory viruses. Nat. Biotechnol. 42, 1765\u20131767 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1375_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1242\/jcs.193482","volume":"130","author":"MM France","year":"2017","unstructured":"France, M. M. & Turner, J. R. The mucosal barrier at a glance. J. Cell Sci. 130, 307\u2013314 (2017).","journal-title":"J. Cell Sci."},{"key":"1375_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-023-06937-1","volume":"626","author":"I Uddback","year":"2024","unstructured":"Uddback, I. et al. Prevention of respiratory virus transmission by resident memory CD8(+) T cells. Nature 626, 392\u2013400 (2024).","journal-title":"Nature"},{"key":"1375_CR42","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S2213-2600(23)00349-1","volume":"11","author":"F Zhu","year":"2023","unstructured":"Zhu, F. et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 11, 1075\u20131088 (2023).","journal-title":"Lancet Respir. Med."},{"key":"1375_CR43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/14760584.2024.2326094","volume":"23","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines. Expert Rev. Vaccines 23, 362\u2013370 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"1375_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00232-006-0861-0","volume":"211","author":"H Fischer","year":"2006","unstructured":"Fischer, H. & Widdicombe, J. H. Mechanisms of acid and base secretion by the airway epithelium. J. Membr. Biol. 211, 139\u2013150 (2006).","journal-title":"J. Membr. Biol."},{"key":"1375_CR45","doi-asserted-by":"publisher","first-page":"9927","DOI":"10.1073\/pnas.1019037108","volume":"108","author":"K Baker","year":"2011","unstructured":"Baker, K. et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 108, 9927\u20139932 (2011).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"1375_CR46","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","volume":"24","author":"J Meinhardt","year":"2020","unstructured":"Meinhardt, J. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 24, 168\u2013175 (2020).","journal-title":"Nat. Neurosci."},{"key":"1375_CR47","doi-asserted-by":"crossref","unstructured":"Ueha R., et al. Oral SARS-CoV-2 inoculation causes nasal viral infection leading to olfactory bulb infection: an experimental study. Front. Cell Infect. Microbiol. 12, 924725 (2022).","DOI":"10.3389\/fcimb.2022.924725"},{"key":"1375_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.25807","volume":"88","author":"IJ Koralnik","year":"2020","unstructured":"Koralnik, I. J. & Tyler, K. L. COVID-19: a global threat to the nervous system. Ann. Neurol. 88, 1\u201311 (2020).","journal-title":"Ann. Neurol."},{"key":"1375_CR49","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/imr.13379","volume":"328","author":"G Hale","year":"2024","unstructured":"Hale, G. Living in LALA land? Forty years of attenuating Fc effector functions. Immunol. Rev. 328, 422\u2013437 (2024).","journal-title":"Immunol. Rev."},{"key":"1375_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01155-4","volume":"10","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters. NPJ Vaccines 10, 100 (2025).","journal-title":"NPJ Vaccines"},{"key":"1375_CR51","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.immuni.2010.02.013","volume":"32","author":"B Damdinsuren","year":"2010","unstructured":"Damdinsuren, B. et al. Single round of antigen receptor signaling programs naive B cells to receive T cell help. Immunity 32, 355\u2013366 (2010).","journal-title":"Immunity"},{"key":"1375_CR52","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.tibtech.2024.05.004","volume":"42","author":"M-Y Kim","year":"2024","unstructured":"Kim, M.-Y., Mason, H. S., Ma, J. K. C. & Reljic, R. Recombinant immune complexes as vaccines against infectious diseases. Trends Biotechnol. 42, 1427\u20131438 (2024).","journal-title":"Trends Biotechnol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01375-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:09:06Z","timestamp":1771549746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01375-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01375-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7498404\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}